Acrivon Therapeutics
ACRV
ACRV
53 hedge funds and large institutions have $21.2M invested in Acrivon Therapeutics in 2025 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 11 increasing their positions, 17 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
53
Holders Change
-9
Holders Change %
-14.52%
% of All Funds
0.71%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
11
Reduced
17
Closed
24
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Renaissance Technologies
New York
|
$606K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
$455K |
| 3 |
Jane Street
New York
|
$371K |
| 4 |
Millennium Management
New York
|
$353K |
| 5 |
Two Sigma Investments
New York
|
$216K |
Top Sellers
| 1 |
PA
Perceptive Advisors
New York
|
$0 |
| 2 |
BlackRock
New York
|
$485K |
| 3 |
Marshall Wace
London,
United Kingdom
|
$216K |
| 4 |
State Street
Boston,
Massachusetts
|
$79.9K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
$196K |
